GAD2 and COVID-19: Furthermore, antibodies against NMDAR, brain-derived neurotrophic factor (BDNF), glutamic acid decarboxylase (GAD65), and the dopamine 1 (D1) receptor were increased in patients with severe COVID-19 and in those requiring oxygen [3].